Medical supply company Baxter International agreed to buy Sanofi’s Seprafilm unit, which makes specialist surgical products, for $350 million in cash.

Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors, and the early thinking on biotech is yes.

Dublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments.

Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.

Pliant Therapeutics and Novartis reached a strategic collaboration and license deal to develop and commercialize integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis (NASH).

Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.

UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.

Allogene Therapeutics inked a research collaboration deal with Stanford University to work on a novel nucleic acid delivery system for CAR-T therapy.

Denmark’s Lundbeck agreed to buy Alder BioPharmaceuticals in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.

GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.